Ortho Regenerative $ORTH Now In The Regulatory Lead For Technologies Addressing A $12B Market

Have you ever torn a:   ● muscle   ● rotator cuff   ● meniscus  ● cartilage    How about someone you know?  Or a favourite athlete?   We wouldn’t blame you if you thought the care and repair of these kinds of injuries is standard and highly successful …. but you would be wrong.   There is a MASSIVE problem with surgery failure rates for each of these as follows:   ● Rotator Cuff   50-60%  ● Meniscus         20-40%  ● Cartilage         15-35%   Ortho Regenerative Technologies $ORTH  $ORTIF believes it has found the solution to this multi-billion dollar problem thanks to its proprietary RESTORE technology platform which dramatically improves the success rate of orthopedic and sports medicine surgeries. $ORTH IS IN THE REGULATORY LEAD FOR REGENERATIVE PRODUCTS  More than just lip service $ORTH has made 3 key announcements in the last 6 months as follows:    1.  Received FDA Clearance To Proceed With U.S. Clinical Trial.   2.  Entered Into A Material Transfer Agreement With A Global Strategic Medical Company For Its Rotator Cuff Tear Repair Phase I/II U.S. Clinical Trial   3.  Received Key U.S. Patent For Its Soft Tissue Repair Platform The importance of these are as follows:  3RD PARTY VALIDATION - $ORTH AGREEMENT WITH A GLOBAL STRATEGIC MEDICAL COMPANY FOR ITS ROTATOR CUFF TEAR REPAIR PHASE I/II U.S. CLINICAL TRIAL  The $ORTH Material Transfer Agreement ("MTA") is with an undisclosed, industry-leading, global strategic medical company for the exclusive use of their proprietary platelet-rich plasma ("PRP") system in Ortho's upcoming ORTHO-R rotator cuff tear ("RCT") repair, phase I/II U.S. clinical trial. The Strategic Company will provide the PRP system disposable kits for all enrolled patients in the study as well as technical and training support. $ORTH, in return, has provided the Strategic Company with a right of "first offer" to distribute ORTHO-R in combination with their proprietary PRP System.   KEY U.S. COMPOSITION AND METHOD PATENT FOR ORTHO-R SOFT TISSUE REPAIR PLATFORM  The Company’s announcement of the receipt of Key U.S composition and method patent for ORTHO-R Soft tissue repair platform is of critical importance for the following 3 reasons:  ● New patent issued by U.S. Patent and Trademark Office protects core IP until 2035 ● Positions Company as leading player in the dynamic regenerative medicine market ● Enables delivery of PRP in soft tissue repair surgery in a proprietary way   $ORTH IS ATTACKING AND IN THE LEAD OF A MULTI BILLION $$ MARKET   In terms of Soft Tissue Repair this is a massive market opportunity as follows:   ROTATOR CUFF TEAR – SHOULDER DYSFUNCTION AND PAIN  • 4m patients in the U.S. alone  • 600,000 annual surgeries in the U.S. alone  • $600m+ market opportunity    MENISCUS TEAR – PAINFUL AND COMPROMISES KNEE FUNCTION  • 1.2m surgeries annually in U.S. alone  • $1bn+ market opportunity   CARTILAGE LESIONS REPAIR – LESIONS CAUSE FRICTION AND PAIN  • 1.2m detected lesions annually in U.S. alone  • 120,000 surgeries and a lack of options  • $1bn+ market opportunity   TENDINOPATHY  ● 50% of sports related injury are tendon related  ● 8  million tendon injuries in US per year  ● $8B+ market opportunity ($1K/unit, 90%+ margin)   Watch this great presentation with Ortho Regenerative Technologies CEO Philippe Deschamps